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Epidemiological as well as clinical and experimental data identified the insulin-like growth
factors (IGF1, IGF2) as important players in gynecological cancers in general, and endome-
trial tumors in particular. The IGF1 receptor (IGF1R), which mediates the proliferative and
anti-apoptotic activities of both ligands, emerged in recent years as a promising therapeu-
tic target in oncology. However, most clinical trials conducted so far led to mixed results,
emphasizing the need to identify biomarkers that can predict responsiveness to anti-IGF1R-
targeted therapies. This article will review recent data regarding the role and expression
of IGF system components in endometrial cancer. In addition, we will review data on
the interplay between the IGF signaling pathway and tumor suppressors p53 and breast
cancer susceptibility gene-1 (BRCA1). Anti-oncogenes p53 and BRCA1 play a key role in
the etiology of gynecological cancers and, therefore, their interaction with IGF1R is of
high relevance in translational terms. A better understanding of the complex mechanisms
underlying the regulation of the IGF system will improve our ability to develop effective
treatment modalities for endometrial tumors.
Keywords: insulin-like growth factors, IGF1, IGF1 receptor, endometrial cancer, uterine serous carcinoma, p53,
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ENDOMETRIAL CANCER
Endometrial cancer is the most widespread gynecologic cancer in
Western countries. Women have a 2–3% lifetime risk of develop-
ing this malignancy. More than 40,000 new cases were diagnosed
in the USA in 2009 and more than 52,600 cases were estimated
to be diagnosed in 2014 (1). As illustrated by these figures, the
incidence of the disease has been increasing over the past decades,
presumably because of the growing obesity epidemic. The impact
of obesity and diabetes on endometrial cancer risk will be dis-
cussed below. Endometrial cancers are classified into two major
categories based on histological parameters, clinical behavior and
epidemiology (Table 1). Type I tumors are estrogen-related and
account for more than 80% of the cases (2, 3). These tumors
exhibit an endometrioid, well-differentiated morphology and are
usually associated with a relatively good prognosis. Type II tumors,
on the other hand, display a less differentiated phenotype and
bear a worse prognosis. Uterine serous carcinoma (USC) consti-
tutes the predominant histological class among Type II tumors.
Although USC represents only 10% of all endometrial cancers, it
accounts for more than 50% of all relapses. USC is considered
as a high grade cancer and has a significantly poorer progno-
sis than endometrioid tumors, with a 5-year survival rate of
55% (4).
Abbreviations: AR, androgen receptor; BMI, body mass index; BRCA1, breast can-
cer susceptibility gene-1; ER, estrogen receptor; IGF1, insulin-like growth factor-1;
IGF1R, IGF1 receptor; IGFBP, IGF-binding protein; INSR, insulin receptor; IRS-
1, insulin receptor substrate-1; PR, progesterone receptor; TKI, tyrosine kinase
inhibitor; USC, uterine serous carcinoma.
A number of molecular alterations have been linked to endome-
trial malignancies. Some of these defects are specific to either Type
I or II tumors, although there is a certain overlap in some of
the aberrations. Type I tumors are often estrogen receptor (ER)
positive, diploid, microsatellite unstable and have KRAS, PTEN,
and/or β-catenin mutations. Type II tumors are usually aneu-
ploid, with alterations in CDK2A, p53, and ERBB2 (5, 6). Loss
of ER and/or progesterone receptor (PR), loss of CDKN2A, and
over-expression of p53 and ERBB2 are associated with decreased
survival of Type II patients (7–10). Women with recurrent and/or
metastatic endometrial cancer of either type have a poor progno-
sis, with a median survival of 7–12 months (11). These patients
require more effective systemic therapy than is presently avail-
able. Currently, adjuvant and systemic treatment of recurrent
and metastatic endometrial cancer are based on conventional
chemotherapy and anti-hormonal treatment. As indicated above,
the growing obesity epidemic in recent decades had a major impact
on endometrial cancer incidence in most developed countries. The
role of obesity, hyperinsulinemia, and diabetes on endometrial
cancer biology will be described in the context of the insulin-like
growth factor (IGF) system.
IGF SYSTEM IN NORMAL UTERINE PHYSIOLOGY
The IGFs constitute a network of cellular and secreted proteins
with essential biological functions (12, 13). Since their discov-
ery in 1957 by Salmon and Daughaday, the IGFs have attracted
vast scientific awareness (14). Interest in this family of hormones,
cell-surface receptors, and circulating and membrane-bound IGF-
binding proteins (IGFBPs) stems mainly from the recognition that
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Table 1 | Classification of endometrial cancers.
TYPE ITUMORS
80% of cases
Estrogen-dependent
Endometrioid, well-differentiated morphology
Usually good prognosis
Estrogen receptor positive, diploid, microsatellite unstable
Include KRAS and/or PTEN mutations
TYPE IITUMORS
10% of cases
Less differentiated phenotype
Often serous papillary histology
Worse prognosis
Often aneuploid with alterations in CDK2A, p53, and ERBB2
the IGF signaling pathways are involved in multiple, clinically rel-
evant, pathophysiological processes in the areas of endocrinology,
pediatrics, aging, and oncology (15–19). IGF1, which was initially
identified by its ability to mediate the effects of growth hormone on
cartilage sulfation and longitudinal growth, is produced mainly in
the liver. Many organs, however, possess the biosynthetic machin-
ery necessary to produce the hormone at various levels. Locally
produced IGF1 and IGF2 are mainly involved in organ-specific,
autocrine, and paracrine types of activities. Both IGF1 and IGF2
ligands activate a common receptor, the IGF1 receptor (IGF1R),
which signals mitogenic, anti-apoptotic, and transforming activi-
ties. The IGF1R is a cell-surface tyrosine kinase receptor coupled
to several intracellular secondary messenger pathways, including
the ras–raf–MAPK and PI3K–AKT signaling cascades. The IGF1R
is vital for cell survival, as illustrated by the lethal phenotype of
mice in which the IGF1R gene is disrupted.
In the context of normal uterine physiology, the IGF axis has
a major regulatory role. IGF1 has been identified as a potential
mediator of the effects of estradiol on uterine growth and uterine
IGF1 biosynthesis was shown to be directly regulated by local estra-
diol levels. Furthermore, IGF1-targeted gene deletion mice exhibit
a disproportionate reduction in uterine size (16). It is unclear,
however, whether this reduction is due to diminished estradiol
production or, alternatively, to defective estrogen action due to
lack of locally produced IGF1. Of importance, cyclic changes in
IGF1 expression and signaling play key roles in regulating the
transition of the premenopausal endometrium through the pro-
liferative, secretory, and menstrual cycles. Finally, as described in
the next section, there is evidence of a causative linkage between
deregulated expression and activation of IGF system components
and endometrial cancer.
IGF SYSTEM IN ENDOMETRIAL CANCER
Experimental, clinical, and epidemiological evidence indicates that
the IGF signaling pathways are important mediators in the bio-
chemical and molecular chain of events that lead from a pheno-
typically normal cell to one harboring neoplastic traits. While this
general dogma applies to most human malignancies, the activity
of the IGF hormonal network in gynecological tumors is strongly
influenced by interactions with organ-specific factors, in particular
steroid hormones. Studies by several groups have shown that IGF1
has a significant role in both Type I and II endometrial cancers,
emphasizing the importance of altered IGF1R gene expression in
the development of a malignant phenotype (20–23).
IMPACT OF OBESITY AND DIABETES ON ENDOMETRIAL
CANCER
Given the structural and functional correlations between IGF1
and insulin, as well as the fact that both hormones employ iden-
tical signaling mediators, it is necessary to focus on the impact
of obesity and diabetes on endometrial cancer. Diabetes melli-
tus type 2, a condition often associated with chronic endogenous
insulin excess, is a well-established risk factor for certain types of
cancer, including endometrial tumors (24). In addition, at least
40% of endometrial cancers can be attributed to excess body
weight. Epidemiological studies have shown that the metabolic
syndrome and its components (hyperlipidemia, obesity, and high
blood pressure) constitute risk factors not only for diabetes and
cardiovascular diseases, but for cancer as well (25). Women with
a body mass index (BMI) above 32 kg/m2 have a relative risk of
4.0 for the development of endometrial cancer, and women with
a BMI above 35 kg/m2 have a relative risk of 6.0, in comparison
with lean women (BMI under 23). Given the fact that the con-
version of androstenedione to estrone takes place in peripheral
adipose tissue, obese women have elevated values of endogenous
estrogen. High circulating estrogen levels may result in endome-
trial proliferation and hyperplasia leading, potentially, to enhanced
cancer risk (24). However, elevated estrogen levels may not entirely
account for the linkage between obesity and endometrial cancer,
and other obesity-related factors were postulated to be involved
in this connection. In particular, chronic hyperinsulinemia and
insulin resistance were identified as major players in the link
between obesity, lack of physical activity, development of ovarian
androgen excess and, finally, endometrial cancer.
The insulin/IGF pathway, which is usually hyper activated in
obesity and diabetes, is a major player in the chain of events
linking the metabolic syndrome with cancer (12, 17, 26–28). The
insulin-cancer hypothesis postulates that chronic hyperinsuline-
mia, a typical hallmark of diabetes, is one of the leading factors
responsible for the obesity–cancer connection. In the context of
endometrial cancer, high concentrations of circulating insulin can
exert both direct and indirect effects that contribute to the develop-
ment of the tumor. Directly, insulin promotes cell proliferation and
survival through activation of the ras–raf–MAPK and PI3K–AKT
pathways. Indirectly, insulin leads to changes in sex hormones,
including increased estrogen levels, with ensuing reduction in
IGFBP1 levels, a negative regulator of IGF1. The net result of
IGFBP1 downregulation is a major increase in IGF1 activity.
CIRCULATING IGF1 LEVELS
Consistent with a key role in endometrial cancer initiation and
development, Ayabe et al. (29) reported higher IGF1 and lower
IGFBP1 levels in postmenopausal endometrial cancer patients. In
contrast, Petridou et al. (30) reported that endometrial cancer was
positively associated with IGF2 serum levels and inversely asso-
ciated with IGF1. Another case–cohort study that included 250
incident endometrial cancer patients and 465 controls assessed
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the association between endometrial cancer risk and serum lev-
els of IGF1, IGFBP3, insulin, and estradiol (31). Low levels of
free IGF1 and high insulin levels were associated with endome-
trial cancer risk after adjustments for age, hormone therapy use,
and estradiol levels. Both associations were stronger among obese
patients, especially the linkage between insulin and endometrioid
adenocarcinoma. However, other studies did not report corre-
lations between endometrial cancer risk, IGF axis components,
and insulin levels (32). In summary, the large degree of variabil-
ity between studies reflects, on one hand, the complexity of this
hormonal system and, on the other hand, the involvement of addi-
tional (hormonal or other) factors that can either positively or
negatively impinge upon IGF axis components. An additional fac-
tor that may contribute to the conflicting reports is the difficulty
to have a real estimation of IGF1 system activation through the
dosage of IGF1 serum levels. A recently developed IGF1 kinase
receptor activation assay (KIRA) allows assessing circulating IGF1
bioactivity by quantifying phosphorylation of tyrosine residues of
the activated IGF1R after stimulation with human serum in vitro
(33). In summary, more research is needed to firmly establish the
diagnostic and prognostic value of circulating IGF1 in endometrial
cancer.
TISSUE EXPRESSION OF IGF SYSTEM COMPONENTS
A significant increase in IGF1R expression in biopsy specimens
from hyperplastic endometrium and endometrial carcinoma,
in comparison to proliferative endometrium, was reported by
McCampbell et al. (21). This study included 10 women with
proliferative phase endometrium, 7 women with secretory phase
endometrium, and 17 postmenopausal women with endometrial
complex atypical hyperplasia. Similarly, Hirano et al. (20) reported
high IGF1R expression in all types of gynecological cancers. This
study included specimens from 46 endometrial, 32 cervical and
20 ovarian cancers, and 28 normal endometrium. Elevated IGF1R
mRNA expression was observed in 91.3% of endometrial can-
cers. The correlation between IGF1R and IGF2 expression levels
with endometrial cancer stage was investigated in a study that
included specimens from 59 endometrial adenocarcinoma cases,
10 endometrial hyperplasia cases, and 7 normal controls (34).
Consistent with the key role of the IGF system in cancer pro-
gression, IGF1R and IGF2 levels were much higher in advanced
stage (Stages III–IV) malignant tissue compared to early stages or
endometrial hyperplasia. Hence, these studies suggest that over-
expression of the IGF1R and IGF2 genes is associated with poor
outcome in endometrial cancer.
INTERACTIONS WITH STEROID HORMONES
Evidence accumulated in recent years indicates that the biological
activity of the IGF system is strongly associated with estrogen sta-
tus (35). Estrogens increase IGF binding and IGF1R mRNA levels
in breast cancer cells, suggesting that a potential mechanism by
which estrogens stimulate breast tissue proliferation involves sen-
sitization to the mitogenic effects of IGFs by enhancing IGF1R
concentrations (36). In addition, estrogens modulate IGF signal-
ing by regulating the expression of other members of the IGF
family, including ligands, IGFBPs, and insulin receptor substrate-1
(IRS-1) (37).
While the interplay between the IGF and estrogen signal-
ing pathways was initially dissected in breast cancer models,
further studies investigated the impact of estrogens on IGF1
action in additional steroid hormone-dependent cancers, includ-
ing endometrial tumors. Estradiol stimulates proliferation of the
uterine epithelium via a mechanism that involves activation of
the IGF1R (38). In turn, activation of PI3K/PKB leads to cyclin
D1 nuclear accumulation and engagement with the cell cycle
machinery. Nuclear accumulation of cyclin D1 results from the
inhibition of glycogen synthase kinase 3β (GSK3β) activity, caused
by inhibitory phosphorylation by PKB. Given that estradiol is the
main risk factor for endometrial cancer, data are consistent with
the notion that downstream activation of the IGF1-mediated path-
way by mutation could play a major role in the progression to
ER-independent tumors (38).
In addition to estrogens, the IGF1 pathway is tightly regulated
by androgens. The interplay between IGF1R and the androgen
receptor (AR) was mainly investigated in prostate cancer mod-
els. Contradictory results, however, were published regarding the
pattern of IGF1R expression throughout the various stages of
the disease. Thus, whereas a number of studies reported that
the progression of the tumor from an androgen-dependent to an
androgen-independent stage is associated with a major decrease
in IGF1R expression levels, other studies showed sustained up-
regulation of IGF1R (39, 40). The effect of wild type AR on IGF1R
expression was examined by means of co-transfection assays using
AR expression vectors, along with an IGF1R promoter construct.
Results obtained revealed that wild type, but not mutant, AR
increased IGF1R promoter activity (41). Finally, Pandini et al.
(42) reported that androgens induced IGF1R up-regulation via
a non-genomic AR pathway.
INTERACTIONS WITH GROWTH FACTORS AND PEPTIDE
HORMONES
In addition to the interactions of the IGF pathway with steroid
hormones, as described above, the endocrine and local activi-
ties of IGF1 are also modulated by complex, often bidirectional,
interactions with other peptide hormones. A recent study inves-
tigated the association between IGF1R and vascular endothelial
growth factor-C (VEGF-C) expression and lymphatic metas-
tasis in 40 endometrial adenocarcinoma tumors and 14 nor-
mal endometrium samples (43). Immunohistochemical analyses
revealed that IGF1R expression was associated with histological
grade and lymph node metastasis, but not with surgical stage.
Moreover, IGF1R and VEGF-C expressions were correlated in
endometrial adenocarcinomas, and lymphatic vessel density was
closely related to both. Abnormal IGF1R and VEGF-C expres-
sions, therefore, might constitute important markers for lymph
node metastasis of endometrial adenocarcinoma and might be
potentially useful for evaluating disease prognosis.
Insulin-like growth factor-1 and epidermal growth factor
(EGF) downregulation and fibroblast growth factor-2 (FGF2) up-
regulation seem to constitute key features of endometrial cancer
progression, as demonstrated in a collection of 30 cancer speci-
mens that were compared to normal adjacent tissue. Pathologic
disruption of mRNA co-expression patterns supports the notion
of a cross talk between IGF1, EGF, and FGF2 signaling pathways in
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the promotion of endothelial cell proliferation and differentiation
of endometrial cancer (44). Given that IGF1 ligand downregula-
tion is usually correlated with IGF1R up-regulation, above studies
are consistent with constitutive activation of the IGF1R signaling
cascade in endometrial cancer.
REGULATION OF IGF1R GENE EXPRESSION
As alluded above, the typical features of the IGF1R include: (i)
potent anti-apoptotic and mitogenic capabilities (15), (ii) impor-
tant roles in invasion, metastasis, and angiogenesis (17–19), and
(iii) involvement in oncogenic transformation (15, 26). Evidence
in support of a key role of IGF1R in malignancy is provided by the
fact that IGF1R-null fibroblasts (derived from IGF1R KO embryos,
a lethal condition) do not undergo transformation when exposed
to cellular or viral oncogenes (15). The levels of expression of
IGF1R as a determinant of IGF1 and IGF2 action and, in particular,
the biological significance of IGF1R over-expression under patho-
logical conditions, are still open questions. Nevertheless, IGF1R
over-expression is regarded as a “quasi” universal pre-requisite for
oncogenic transformation. This widely accepted viewpoint relies
on the well-established concept that elevated IGF1R levels and
enhanced IGF signaling are key events, indispensable for the cell
to adopt proliferative/oncogenic pathways. Of importance, differ-
ences in IGF1R expression patterns exist between different cancer
types. Thus, IGF1R over-expression is a typical feature of most
pediatric cancers and other solid tumors (e.g., brain and kidney),
whereas the situation with adult epithelial tumors (e.g., breast and
prostate) is more complex and reduced IGF1R levels are often seen
in advanced stage diseases (26).
REGULATION OF IGF1R EXPRESSION BY p53
The p53 pathway is activated in response to a wide variety of cellu-
lar stress signals. These insults include DNA damage and telomere
shortening, hypoxia, spindle damage, heat and cold shock, inflam-
mation, nitric oxide production, and activation of oncogenes by
mutations. These stresses can potentially lead to a decrease in the
fidelity of cell cycle progression and DNA replication, with an
ensuing increase in mutation rates. The convergence of the p53
and IGF signaling pathways has been the focus of considerable
basic and translational interest (45). In a recent study, we evalu-
ated p53 and IGF1R expression in a group of 35 USC patients,
of which 17 had metastatic tumors (22). Immunohistochemical
analysis revealed that IGF1R was highly expressed in primary and
metastatic USC tumors (Figure 1). Positive staining (grades II–IV)
was observed in 94.3% of primary USC tumors and in all metasta-
tic tumors. High IGF1R expression (grades III–IV) was recorded in
42.8% of the primary tumors and 77.8% of the metastatic tumors.
p53 was expressed in 85.7% of primary tumors and 100% of metas-
tases. The staining was strong (grade IV) in 68.6% of primary USC
tumors and in all metastatic tumors (Figure 2).
Survival analyses were conducted to evaluate the impact of p53
and IGF1R expression on endometrial disease prognosis. Data
analysis revealed a negative correlation between p53 expression
and survival. Specifically, 5-year survival was 12% in patients with
strong p53 staining compared to 60% in patients with negative-to-
moderate expression. Mean progression free interval was shorter
in patients with strong p53 staining compared to patients with
low p53 (28 vs. 58.2 months, respectively; p= 0.012) in univari-
ate analysis. Kaplan–Meier survival analysis was performed for
patients whose tumors exhibited over-expression of p53 and for
patients whose tumors did not express p53 (Figure 3). Survival
was significantly shorter in patients whose tumors over-expressed
p53 compared to low p53 expressors (p= 0.009). No correlation
between IGF1R expression and survival was observed.
Finally, to examine the involvement of p53 in regulation of
IGF1R gene expression in USC, the USPC-2 cell line (express-
ing a truncated mutant p53) was transiently co-transfected with a
wild type or mutant p53 expression vector along with an IGF1R
promoter-luciferase reporter plasmid. Results of luciferase mea-
surements indicate that wild type p53 repressed IGF1R promoter
activity by ~65%. Mutant p53, on the other hand, was unable
to inhibit promoter activity. The mechanism of action of p53
was shown to involve interaction with zinc finger protein Sp1,
a potent transactivator of the IGF1R gene. In summary, p53
regulates IGF1R gene expression in endometrial cancer via a
mechanism that involves repression of the IGF1R promoter. The
interplay between the p53 and IGF signaling pathways has major
translational relevance. Pathologic deregulation of IGF1R gene
expression as a result of tumor-specific, loss-of-function p53 muta-
tions may lead to increased cell-surface IGF1R concentrations
and enhanced IGF1R phosphorylation by locally produced and/or
endocrine IGF1 and IGF2. As mentioned above, IGF1R activation
constitutes a cardinal step in tumor progression (Figure 4). Elu-
cidation of the transcription mechanisms and factors responsible
FIGURE 1 | Immunohistochemical staining of IGF1R in primary
and metastatic USC. (A) Primary tumor, neoplastic glands (arrows)
adjacent to non-neoplastic endometrial glands (asterisks). H&E,
×200. (B) Primary tumor, weak cytoplasmic staining in <50% of
cells (grade II) in neoplastic glands. Moderate staining in >50% of
cells in adjacent non-neoplastic glands. (C) Metastasis, moderate
cytoplasmic staining in nearly all neoplastic cells. (D) Metastasis, a
focus of increased atypia. Moderate and strong staining in all
neoplastic cells. Some of the immunohistochemical figures were
shown in Ref. (22).
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FIGURE 2 | Immunohistochemical staining of p53 (A–D) and BRCA1
(E–H) in primary and metastatic USC. p53: (A) Metastasis, a focus of
increased atypia in metastatic tumor. Enlarged, pleomorphic and bizarre
nuclei, atypical mitoses. H&E, ×400. (B) Primary tumor, strong nuclear
staining in nearly all neoplastic cells (grade IV). No staining in adjacent
non-neoplastic glands. (C) Metastasis, strong nuclear staining in nearly all
neoplastic cells (grade IV). (D) Metastasis, a focus of increased atypia. Very
strong staining in all neoplastic cells (grade IV). BRCA1: (E) Primary tumor,
neoplastic glands (arrows) adjacent to non-neoplastic endometrial glands
(asterisks). H&E, ×200. (F) Primary tumor, moderate cytoplasmic staining in
>50% of cells in neoplastic and non-neoplastic glands. (G) Metastasis,
moderate and strong cytoplasmic staining in nearly all neoplastic cells.
(H) Metastasis, a focus of increased atypia, strong staining in all neoplastic
cells. Immunohistochemistry data were shown in Ref. (23).
FIGURE 3 | Kaplan–Meier survival curve for p53-overexpressing and
non-expressing tumors in women with USC.
for IGF1R gene expression will help to improve our ability to
deliver IGF1R-directed therapies. These analyses, in addition, will
be invaluable in predicting responsiveness to these therapies.
FIGURE 4 | Proposed model of p53 regulation of IGF1R gene
expression. Tumor suppressor p53 is a negative cell cycle regulator that
prevents passage of damaged DNA to daughter cells. Wild type p53
suppresses IGF1R gene transcription, leading to reduced IGF1R levels and
a decrease in IGF1- and IGF2-stimulated IGF1R phosphorylation. As a net
result, cell proliferation is reduced and apoptosis is increased (left panel).
Loss-of-function or gain-of-function mutations of p53 are common events in
cancer (right panel). Mutant forms of p53 are able to transactivate the
IGF1R gene, with ensuing increase in IGF1R biosynthesis. Augmented
IGF1R expression and activation is a pre-requisite for tumor growth and is
usually associated with abrogation of apoptosis (i.e., enhanced cell
survival). A similar paradigm applies for BRCA1.
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REGULATION OF IGF1R EXPRESSION BY BRCA1
Breast cancer susceptibility gene-1 is a tumor suppressor gene
whose mutation has been associated with the appearance of breast
and/or ovarian cancer at young ages. Breast cancer susceptibil-
ity gene-1 (BRCA1) participates in multiple biological pathways
including DNA damage repair, transcriptional control, cell growth,
and apoptosis (46). Similar to the paradigm described above
for p53, BRCA1 has been shown to inhibit IGF1R transcription
in breast, osteosarcoma, and ovarian cancer cell lines (47–49).
These results suggest that a potential mechanism of action of
BRCA1 involves suppression of IGF1R gene expression. In con-
trast, mutant BRCA1 proteins lack transcriptional activity and are
impaired in their ability to suppress the IGF1R promoter, with
resulting increases in IGF1R mRNA and IGF binding in mam-
mary tumors. Consistent with the postulate that mutant BRCA1
may lead to deregulated IGF1R expression, a recent immunohis-
tochemical analysis revealed significantly elevated IGF1R levels in
primary breast tumors derived from BRCA1 mutation carriers,
compared to sporadic tumors (50).
In the context of endometrial tumors, we investigated the rate
of three predominant BRCA1/2 mutations in Jewish patients with
USC and the relevance of carrier status to clinico-pathological
features and survival (51). Overall, 8 of 31 patients (25.8%)
included in the study were mutation carriers. Four were BRCA2
(6174delT) carriers and two each carried the BRCA1 (185delAG)
and the BRCA1 (5382InsC) mutations. Given the high incidence
of BRCA mutations in USC patients, it has been postulated that
USC could be considered an integral component of the hereditary
breast–ovarian cancer syndrome.
To investigate BRCA1 expression in USC and its correlation
with IGF1R, immunohistochemical stainings were conducted in
USC samples in paraffin blocks. The group comprised 35 patients
with histologically confirmed USC, including 17 patients with
metastases. Results revealed high BRCA1 expression in primary
and metastatic USC (23). BRCA1 staining was mainly cyto-
plasmic. BRCA1 was expressed in all primary and metastatic
tumors with strong staining in 71% (25/35) of primary tumors
and 82.4% (14/17) of metastatic tumors. Metastatic tumors
stained more intensely for BRCA1 (82.3% strong staining) com-
pared to primary tumor sites (71.4% strong staining; p= 0.041;
Figure 3).
To investigate the effect of BRCA1 on IGF1R promoter in
endometrial cancer cells, co-transfection assays were performed
using a BRCA1 expression vector along with an IGF1R promoter
reporter (23). Results revealed that BRCA1 over-expression led to
46–65% decline in IGF1R promoter activity in two USC-derived
cell lines. Measurement of endogenous IGF1R protein in USC cells
corroborated the inhibitory role of BRCA1 on IGF1R expression
and emphasized the physiological relevance of these results. Fur-
thermore, BRCA1 over-expression led to a reduction in phospho-
Akt, an important downstream mediator of IGF1R. In summary,
these data emphasize the notion that tumor suppressor BRCA1 is
involved in controlling the expression and action of the IGF axis in
endometrial cancer. The convergence of IGF1R-mediated cell sur-
vival pathways and BRCA1-mediated tumor protective pathways
is of major basic and clinical relevance.
IGF1 AXIS TARGETING IN ENDOMETRIAL CANCER
IGF1 receptor targeting emerged in recent years as a very active area
in cancer therapeutics. IGF1R targeting is expected to result in: (i)
inhibition of IGF1R expression; (ii) blockade of ligand–receptor
interaction; and/or (iii) impairment of receptor activation. Tar-
geting methods are evaluated for their ability to: (i) inhibit cancer
cell proliferation, survival, and anchorage-independent growth
in vitro; (ii) reverse tumor growth and metastasis formation
in vivo; and (iii) sensitize cancer cells to chemotherapy, radiother-
apy, hormonal, and biological therapies. Various methodologies
are currently being evaluated for their ability to down-regulate
IGF1R expression and signaling. The most promising approaches
at present are IGF1R monoclonal antibodies and IGF1R-selective
low molecular weight tyrosine kinase inhibitors (TKIs). Human-
ized IGF1R antibodies are designed to prevent IGF1 binding, with
ensuing receptor degradation, whereas TKI, on the other hand,
are designed to inhibit IGF1R kinase activity without affecting
receptor expression (52–60).
Several IGF1R antibodies were evaluated in Phase 1–3 clinical
trials as monotherapy, as well as in combination with chemother-
apy, radiotherapy, and/or additional antibodies. Currently, the
greatest clinical impact of IGF system signaling inhibition for
cancer treatment is prevention or reversal of resistance to anti-
cancer therapies. Therapies directed against the IGF1R were shown
to enhance the cytotoxic effects of conventional treatments. In
a Phase 1 study of AMG-479 (Ganitumab, Amgen, a mono-
clonal IGF1R antibody) that enrolled 33 epithelial ovarian can-
cer patients, 3 had an objective response and 5, stable disease
(NCT00718523). The dose-limiting toxicity of this agent was
thrombocytopenia; additional adverse effects included arthralgia,
diarrhea, and hyperglycemia (52). Two Phase 1 trials evaluated
the activity of CP-751, 871 (figitumumab, Pfizer), an IGF1R mon-
oclonal antibody, in combination with docetaxel or carboplatin
and paclitaxel in patients with advanced solid tumors and reported
that this drug combination was well tolerated (53). Phase 1 and
2 trials in small cell lung cancer, colorectal, pancreatic, and ovar-
ian cancers and in other solid tumors are currently underway.
However, few of these trials have progressed to or completed
Phase 3 studies. Two Phase 3 trials testing figitumumab in con-
junction with chemotherapy or combined with EGF receptor
inhibitor (erlotinib) in advanced and in relapsed non-small cell
lung cancer, were discontinued after data showed significant side
effects (54).
Although most of these antibodies do not bind to the insulin
receptor (INSR), some of them partially cross-react with the INSR
leading to hyperglycemia in clinical studies. The potential effect of
IGF1R antibodies on INSR signaling is of special concern, given
that these antibodies can co-target or alter INSR function, leading
to insulin resistance and adverse effects on glucose and carbohy-
drate metabolism. On the other hand, INSR targeting could be
potentially advantageous, because specific inhibition of the INSR
in the tumor might increase the effective anti-tumoral activity
(27, 28, 55). Preliminary results from Phase 1 trials in patients
with advanced cancer treated with CP-751, 871 or IM Clone’s A12
antibodies showed only infrequent, mild, transient hyperglycemia,
with no dose-limiting toxicity.
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In addition to IGF1R antibodies, a series of low molecu-
lar weight TKIs have demonstrated tumor growth inhibitory
properties in experimental models. In general, these therapies
indiscriminately inhibit both IGF1R and INSR kinase domains,
as these enzymatic domains are closely related (56). However,
several TKI are more selective to the IGF1R and have a 15-
to 30-fold increased potency for IGF1R kinase inhibition com-
pared to INSR kinase inhibition (57). NVP-AEW541 (Novartis
AG, Basel, Switzerland), an orally available, IGF1R-specific TKI,
inhibited IGF1R signaling in tumor xenografts and significantly
reduced the growth of IGF1R-driven sarcomas (57). OSI-906
(Astellas Pharma Inc., Tokyo, Japan) is a potent, selective, orally
bioavailable, dual IGF1R/INSR TKI, which has demonstrated
in vivo efficacy in tumor models and is currently in clinical
evaluation.
Several in vivo studies demonstrated that inhibition of the IGF1
and IGF2 ligands using neutralizing antibodies resulted in potent
antitumor activity and offer an effective approach to selectively
target both the IGF1R and INSR-A signaling pathways (58). How-
ever, only MEDI-573, a fully human antibody that neutralizes IGF1
and IGF2 and inhibits IGF signaling through both pathways, pro-
gressed into clinical studies (advanced solid tumors and metastatic
breast cancer). To the best of our knowledge, this targeted strategy
has never been evaluated in gynecologic malignancies.
As mentioned above, there is a tight interaction between the
insulin and IGF1 pathways (59, 60). In fact, both INSR and
IGF1R share most of their downstream cytoplasmic mediators.
Metformin (N,N -dimethylbiguanide), an oral anti-hyperglycemic
agent of the biguanides family, is undergoing a renaissance because
of its potential as a cancer therapy, along with its traditional role in
treating diabetes. Recent studies reported that metformin use was
associated with a significant decrease in the incidence of cancer
(61). In vitro studies suggested that metformin inhibits cancer cell
growth by activating adenosine monophosphate protein kinase
(Ampk), by inactivating the mammalian target of rapamycin
(mTOR), and by decreasing the activity of the mTOR effector S6K1
(62). In the specific context of endometrial cancer, studies demon-
strated a significant antiproliferative activity of metformin in Type
I endometrial cancer. Cantrell et al. (63) reported that metformin
treatment resulted in G1 arrest, apoptosis and decreased cell pro-
liferation in ECC and Ishikawa endometrial cells. This effect was
partially mediated through Ampk activation and subsequent inhi-
bition of the mTOR pathway. Furthermore, metformin was shown
to enhance the sensitivity of type I endometrial cells to cisplatin
and taxol chemotherapy (64, 65).
In a recent study, we explored the effects of metformin in USC
cells. Our data provided evidence that metformin down-regulated
the expression of both IGF1R and INSR. In addition, metformin
induced apoptosis and inhibited proliferation and migration of
USC cell lines including both wild type and mutant p53. These
data suggest that metformin therapy could be a novel and attractive
therapeutic approach for endometrial cancer, in general, and USC,
in particular (66). Of interest, a recent study demonstrated that
metformin inhibits IGF1R up-regulation in prostate cancer cells
via a mechanism that involves disruption of membrane-initiated
androgen signaling (67).
Finally, vorinostat, also known as suberanilohydroxamic acid
(SAHA), is a novel histone deacetylase inhibitor, representing a
new class of potential antitumor agents (68). Vorinostat induced
growth arrest, differentiation, and apoptosis in a variety of trans-
formed cells, including prostate, leukemia, breast, and colon can-
cers. Vorinostat has undergone evaluation in a number of clinical
trials (69). In endometrial cancer, the combination of vorinos-
tat and caspase-8 inhibitor led to high anti-tumoral activity (70).
In a recent study, we evaluated the antiproliferative activity of
vorinostat in Type I and II endometrial cancer cells (71). Vorino-
stat treatment induced apoptosis in both cell types, abolished the
anti-apoptotic activity of IGF1, and led to a significant decrease in
colony forming capability.
IDENTIFICATION OF BIOMARKERS
As mentioned above, the IGF axis has gained interest as a risk
factor with a potential role in the progression of endometrial car-
cinoma. Several studies showed a significant correlation between
components of the IGF system and endometrial cancer risk (20,
29, 59). Nevertheless, the response to therapy targeting IGF1R
was relatively low due to the lack of predictive tumor biomarkers
that could assist in selecting patients who would benefit from the
proposed treatment. Growing clinical evidence suggests a poten-
tial correlation between biomarkers related to the IGF1R pathway
and clinical benefits from IGF1R-targeted therapies. High IGF1R
expression and elevated circulating IGF1 levels were shown to be
correlated with improved response to IGF1R-targeted therapies
(72, 73). In addition, increased IGF1R nuclear localization was
associated with better overall survival in sarcoma patients treated
with IGF1R antibody (74). In a recent review, Michael Pollak sug-
gested that IGF1R levels and the presence of IGF1R autocrine loops
are possible predictive biomarkers for IGF1R-targeted therapy
(60). It was also suggested that the presence of activating mutations
downstream of IGF1R would induce resistance to IGF1R-targeted
therapy.
As discussed above, our studies provided evidence for func-
tional and physical interactions between the IGF signaling path-
ways and tumor suppressors p53 and BRCA1. We demonstrated
that IGF1R gene transcription rate is dependent on a number
of stimulatory nuclear proteins and is also modulated by neg-
ative transcriptional regulators, including p53/p63/p73 (45, 75)
and BRCA1 (46–50). The level of expression of the IGF1R gene
is ultimately determined by complex interactions between stimu-
latory and inhibitory transcription factors. Aberrant deregulation
of these regulatory loops can lead to enhanced IGF1R expres-
sion, a pre-requisite for malignant transformation. Furthermore,
it was demonstrated that the mutational status of p53 and, prob-
ably, BRCA1 has a major impact on response to IGF1R-targeted
therapy (22, 23). Finally, the potential role of p53 and BRCA1/2
as biomarkers for IGF1R-directed therapies in endometrial can-
cer (and most likely other types of cancer) must be confirmed by
larger cell-based and patient analyses.
CONCLUSION
It is well-established that the IGF hormonal network plays an
important role in normal cell growth and differentiation as well
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as in the establishment and maintenance of a malignant pheno-
type. Changes in IGF1 expression and signaling play key roles
in the regulation of normal uterine physiology. In addition,
there is a causative linkage between deregulated expression and
activation of IGF axis components and endometrial cancer. As
a corollary, targeted IGF1R therapy has emerged as a biologi-
cally plausible approach. The physical and functional interactions
between circulating and locally produced IGF components and
steroid hormones and their receptors are of major importance
under both physiological and pathological conditions. Likewise,
control of IGF1R expression and action by tumor suppressors
(e.g., p53, BRCA1) involved in the etiology of gynecological can-
cer has a major impact on cell’s fate and, consequently, is of
high translational relevance. Further basic and clinical research
is needed to achieve better therapeutic outcomes in endometrial
cancer.
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